Health Insurers Opt-Out of BALANCE Model and Its Implications

Two major health insurers, United Health and Aetna, have opted out of participating in the Trump administration's BALANCE model. This pilot program was designed to provide some Medicare beneficiaries with access to GLP-1 obesity medications. The insurers' decision, announced by the April 20 deadline, indicates potential challenges for the initiative due to the insufficient commitment from Medicare Part D prescription drug plans, which are crucial for its implementation.

The BALANCE model aimed to align with former President Trump's broader objective of reducing drug prices by offering affordable GLP-1 medications. However, consumer advocacy group Public Citizen argues that significant price reductions would necessitate alternative strategies. They propose employing Section 1498, which allows the authorization of generic competition for patented drugs, potentially driving prices down through increased competition.

Peter Maybarduk, directing the Access to Medicines program at Public Citizen, expressed skepticism about the administration's efforts to genuinely reduce prices. He emphasized the need to hold pharmaceutical companies accountable, noting that agreements with companies like Eli Lilly and Novo Nordisk facilitated expedited FDA reviews after promises to lower Medicare prices—a promise jeopardized by the insurers' withdrawal. Public Citizen continues to advocate for using existing legal measures to introduce cost-effective generics, warning that inaction could lead to increased expenses for Medicare and Medicaid, thereby limiting patient access to necessary treatments.